These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34826558)

  • 21. Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study.
    Dold M; Bartova L; Fugger G; Mitschek MM; Fabbri C; Serretti A; Mendlewicz J; Souery D; Zohar J; Montgomery S; Kasper S
    J Affect Disord; 2022 Jan; 296():485-492. PubMed ID: 34653701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pramipexole augmentation in treatment-resistant major depressive disorder.
    Pae CU
    Expert Rev Neurother; 2014 Jan; 14(1):5-8. PubMed ID: 24308279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy].
    Erbe S; Gutwinski S; Bschor T
    Psychiatr Prax; 2012 Mar; 39(2):57-63. PubMed ID: 22189902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brexpiprazole as an augmentation agent to antidepressants in treatment resistant major depressive disorder.
    Cha DS; Luo X; Ahmed J; Becirovic L; Cha RH; McIntyre RS
    Expert Rev Neurother; 2019 Sep; 19(9):777-783. PubMed ID: 31389279
    [No Abstract]   [Full Text] [Related]  

  • 25. Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.
    Lin CY; Tsai GE; Wang HS; Wu YH; Chiou CC; Wu VY; Lane HY
    J Clin Psychiatry; 2014 Sep; 75(9):e924-31. PubMed ID: 25295435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic potential of new second generation antipsychotics for major depressive disorder.
    McElroy SL; Guerdjikova A; Mori N; Keck PE
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1527-44. PubMed ID: 21105856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prescribing patterns of antidepressants, antipsychotics and mood stabilizers in bipolar patients misdiagnosed with major depressive disorder in China.
    Xiang YT; Hu C; Wang G; Zheng QW; Fang YR; Ungvari GS; Kilbourne AM; Lai KY; Si TM; Chen DF; Lu Z; Yang HC; Hu J; Chen ZY; Huang Y; Sun J; Wang XP; Li HC; Zhang JB; Chiu HF
    Hum Psychopharmacol; 2012 Nov; 27(6):626-31. PubMed ID: 23027671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melancholic features in major depression - a European multicenter study.
    Dold M; Bartova L; Fugger G; Kautzky A; Mitschek MMM; Fabbri C; Montgomery S; Zohar J; Souery D; Mendlewicz J; Serretti A; Kasper S
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Aug; 110():110285. PubMed ID: 33609603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medication use patterns and two-year outcome in first-admission patients with major depressive disorder with psychotic features.
    Craig TJ; Grossman S; Bromet EJ; Fochtmann LJ; Carlson GA
    Compr Psychiatry; 2007; 48(6):497-503. PubMed ID: 17954133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex-related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression.
    Bartova L; Dold M; Fugger G; Kautzky A; Mitschek MMM; Weidenauer A; Hienert MG; Frey R; Mandelli L; Zohar J; Mendlewicz J; Souery D; Montgomery S; Fabbri C; Serretti A; Kasper S
    Depress Anxiety; 2021 Sep; 38(9):896-906. PubMed ID: 34110066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder.
    Fanelli G; Benedetti F; Kasper S; Zohar J; Souery D; Montgomery S; Albani D; Forloni G; Ferentinos P; Rujescu D; Mendlewicz J; Serretti A; Fabbri C
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jun; 108():110170. PubMed ID: 33181205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.
    McAllister-Williams RH; Anderson IM; Finkelmeyer A; Gallagher P; Grunze HC; Haddad PM; Hughes T; Lloyd AJ; Mamasoula C; McColl E; Pearce S; Siddiqi N; Sinha BN; Steen N; Wainwright J; Winter FH; Ferrier IN; Watson S;
    Lancet Psychiatry; 2016 Feb; 3(2):117-27. PubMed ID: 26727041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systematic review of augmentation strategies for patients with major depressive disorder.
    Fleurence R; Williamson R; Jing Y; Kim E; Tran QV; Pikalov AS; Thase ME
    Psychopharmacol Bull; 2009; 42(3):57-90. PubMed ID: 19752841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Earlier Versus Later Augmentation with an Antipsychotic Medication in Patients with Major Depressive Disorder Demonstrating Inadequate Efficacy in Response to Antidepressants: A Retrospective Analysis of US Claims Data.
    Yermilov I; Greene M; Chang E; Hartry A; Yan T; Broder MS
    Adv Ther; 2018 Dec; 35(12):2138-2151. PubMed ID: 30456519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2.
    Nakamura A; Mihara K; Nagai G; Kagawa S; Suzuki T; Nemoto K; Kondo T
    Ther Drug Monit; 2016 Jun; 38(3):379-82. PubMed ID: 26829597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychotic Features in Patients With Major Depressive Disorder: A Report From the European Group for the Study of Resistant Depression.
    Dold M; Bartova L; Kautzky A; Porcelli S; Montgomery S; Zohar J; Mendlewicz J; Souery D; Serretti A; Kasper S
    J Clin Psychiatry; 2019 Jan; 80(1):. PubMed ID: 30677267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression.
    Bartova L; Fugger G; Dold M; Swoboda MMM; Zohar J; Mendlewicz J; Souery D; Montgomery S; Fabbri C; Serretti A; Kasper S
    J Psychiatr Res; 2021 Sep; 141():167-175. PubMed ID: 34216945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex Differences in Responses to Antidepressant Augmentations in Treatment-Resistant Depression.
    Moderie C; Nuñez N; Fielding A; Comai S; Gobbi G
    Int J Neuropsychopharmacol; 2022 Jun; 25(6):479-488. PubMed ID: 35167671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical issues in use of atypical antipsychotics for depressed patients.
    Pae CU; Patkar AA
    CNS Drugs; 2013 May; 27 Suppl 1():S39-45. PubMed ID: 23709360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.